How it works.
CJC-1295 without DAC — also called Modified GRF (1-29) — is a 29-residue analog of growth-hormone-releasing hormone. Four substitutions relative to native GHRH(1-29) (D-Ala at position 2, Gln at 8, Ala at 15, Leu at 27) protect it from DPP-4 cleavage while preserving GHRH-receptor affinity. It agonizes the GHRH receptor on anterior-pituitary somatotrophs, raising the amplitude of endogenous GH pulses. Unlike the DAC (Drug Affinity Complex) version, which binds albumin and persists for days, the no-DAC form has a short half-life (~30 minutes), so its GH release tracks the body's natural pulsatile rhythm. In research it is most often studied alongside a ghrelin-receptor secretagogue such as ipamorelin, where the two receptor systems produce a larger, more physiological GH pulse than either alone.
The research behind this compound, cited in full.
Provided for context only. None of the studies cited below evaluate hábit material specifically; they document the published literature on the compound and its mechanism. Research-use claims are not therapeutic claims.
- [01] Teichman SL. et al. J Clin Endocrinol Metab 91 (2006): 799–805.
- [02] Sackmann-Sala L. et al. Mol Cell Endocrinol 382 (2014): 220–230.
- [03] Ionescu M. & Frohman LA. J Clin Endocrinol Metab 91 (2006): 4792–4797.
Verified buyer notes.
Initials only — every quote is verified against an order record. We don’t ghost-write reviews.
“COA matched what we ran in-house. Powder reconstituted clean, no haze. Did exactly what we needed it to.”
“Switched after two bad lots from a previous source. Three orders in, zero issues.”
“Asked support a purity question and got the raw HPLC trace back within the hour. That transparency is why we reorder.”
The shared signature.
A 15-amino-acid pentadecapeptide derived from human gastric juice, studied for its effects on tissue repair, vascular signaling, and connective-tissue research.
A synthetic fragment of thymosin beta-4 studied for its effects on cell migration, actin sequestration, and tissue repair signaling.
A 29-amino-acid GHRH analog studied for its effects on endogenous growth-hormone secretion through pituitary GHRH receptor activation.
A selective pentapeptide growth-hormone secretagogue studied for its effects on GH release through the ghrelin/GHS receptor, with minimal impact on cortisol or prolactin.